Alternative formulation for patients with contact reactions to topical 2% and 5% minoxidil vehicle ingredients.
Scheman
A J
AJ
West
D P
DP
Hordinksy
M K
MK
Osburn
A H
AH
West
L E
LE
D000287:Administration, Topical; D000505:Alopecia / Q000175:diagnosis / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D017449:Dermatitis, Allergic Contact / Q000175:diagnosis / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D004339:Drug Compounding; D005260:Female; D006801:Humans; D008875:Middle Aged; D008914:Minoxidil / Q000008:administration & dosage / Q000009:adverse effects / Q000032:analysis* / Q000737:chemistry; D010328:Patch Tests; D014677:Pharmaceutical Vehicles / Q000009:adverse effects* / Q000032:analysis / Q000737:chemistry; D011092:Polyethylene Glycols / Q000032:analysis / Q000737:chemistry; D011379:Prognosis; D019946:Propylene Glycol / Q000009:adverse effects*; D012536:Scalp Dermatoses / Q000139:chemically induced*
D014677:Pharmaceutical Vehicles; D011092:Polyethylene Glycols; D008914:Minoxidil; D019946:Propylene Glycol